WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect
– WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated cytotoxicity (ADCC), providing diverse bioprocessing solutions for global clients – WuXiaADCC PLUSTM is derived from WuXi Biologics’ highly-vetted WuXiaTM cell line platform SHANGHAI, Jan. 25, 2024 /PRNewswire/ — WuXi Biologics (“WuXi […]